natgillin/translations-raw huggingface dataset:
The safety and efficacy of combinations of sildenafil with other PDE5 Inhibitors, or other pulmonary arterial hypertension (PAH) treatments containing sildenafil , or other treatments for erectile dysfunction have not been studied.
Sigurnost i djelotvornost kombinacija sildenafila s drugim inhibitorima PDE5, s drugim terapijama za plućnu arterijsku hipertenziju (PAH) koje sadrže sildenafil ili s drugim oblicima liječenja erektilne disfunkcije nije ispitana.
In these study populations, mean additional reductions of supine blood pressure of 7/7 mmHg, 9/5 mmHg, and 8/4 mmHg, and mean additional reductions of standing blood pressure of 6/6 mmHg, 11/4 mmHg, and 4/5 mmHg, respectively, were observed.
U ispitivanoj populaciji uočena su srednja dodatna sniženja krvnog tlaka u ležećem položaju od 7/7 mmHg, 9/5 mmHg odnosno 8/4 mmHg te srednja dodatna sniženja krvnog tlaka u stojećem položaju od 6/6 mmHg, 11/4 mmHg odnosno 4/5 mmHg.
In a study of the hemodynamic effects of a single oral 100 mg dose of sildenafil in 14 patients with severe coronary artery disease (CAD) (>70 % stenosis of at least one coronary artery), the mean resting systolic and diastolic blood pressures decreased by 7 % and 6 % respectively compared to baseline.
U ispitivanju hemodinamičkih učinaka jednokratne oralne doze sildenafila od 100 mg u 14 bolesnika s teškom bolesti koronarnih arterija (> 70% stenoza barem jedne koronarne arterije), srednji sistolički i dijastolički krvni tlak u mirovanju je snižen za 7%, odnosno 6% u usporedbi s početnom vrijednosti.
Do not use this medicine after the expiry date which is stated on the blister and carton after EXP.
Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na blisteru i kutiji iza „EXP“.
Two clinical studies were specifically designed to assess the time window after dosing during which sildenafil could produce an erection in response to sexual stimulation.
Klinička djelotvornost i sigurnost Dva klinička ispitivanja posebno su dizajnirana kako bi se procijenio vremenski okvir nakon doziranja tijekom kojeg bi sildenafil mogao dovesti do erekcije u odgovoru na seksualnu stimulaciju.
Table 1: Medically important adverse reactions reported at an incidence greater than placebo in controlled clinical studies and medically important adverse reactions reported through postmarketing surveillance
Tablica 1: Medicinski značajne nuspojave zabilježene s učestalošću većom od placeba u kontroliranim kliničkim ispitivanjima i medicinski značajne nuspojave zabilježene u razdoblju nakon stavljanja lijeka u promet Klasifikacija organskih sustava
− If you have ever had loss of vision due to non-arteritic anterior ischaemic optic neuropathy
• Ako ste ikada imali gubitak vida zbog nearteritične prednje ishemijske optičke neuropatije
Poly(vinyl alcohol) Titanium dioxide (E171) Macrogol 3350
Film ovojnica poli(vinilni alkohol) titanijev dioksid (E171) makrogol 3350 talk
Cerebrovascular accident, Transient ischaemic attack, Seizure,* Seizure recurrence,* Syncope
Cerebrovaskularni inzult, tranzitorna ishemijska ataka, napadaji,* ponavljanje napadaja,* sinkopa
To reduce the chance that these symptoms might happen, you should be on a regular daily dose of your alpha-blocker before you start Sildenafil Teva.
Kako bi se smanjila mogućnost pojave tih simptoma, trebate biti na redovitoj dnevnoj dozi alfa-blokatora prije nego počnete uzimati Sildenafil Teva.
Cimetidine (800 mg), a cytochrome P450 inhibitor and non-specific CYP3A4 inhibitor, caused a 56 % increase in plasma sildenafil concentrations when co-administered with sildenafil (50 mg) to healthy volunteers.
(800 mg), inhibitor citokroma P450 i nespecifični CYP3A4 inhibitor, uzrokovao je 56%-tni porast koncentracija sildenafila u plazmi kada se primjenjivao istodobno sa sildenafilom (50 mg) u zdravih dobrovoljaca.
Stevens-Johnson Syndrome (SJS),* Toxic Epidermal Necrolysis (TEN)*
Stevens-Johnsonov sindrom (SJS), *
Across all trials, the proportion of patients reporting improvement on sildenafil were as follows: psychogenic erectile dysfunction (84 %), mixed erectile dysfunction (77 %), organic erectile dysfunction (68 %), elderly (67 %), diabetes mellitus (59 %), ischaemic heart disease (69 %), hypertension (68 %), TURP (61 %), radical prostatectomy (43 %), spinal cord injury (83 %), depression (75 %).
Uzimajući u obzir sva ispitivanja, udio bolesnika koji su prijavili poboljšanje uz sildenafil bio je sljedeći: psihogena erektilna disfunkcija (84%), mješovita erektilna disfunkcija (77%), organska erektilna disfunkcija (68%), starije osobe (67%), dijabetes melitus (59%), ishemična bolest srca (69%), hipertenzija (68%), TURP (61%), radikalna prostatektomija (43%), ozljeda leđne moždine
Serious cardiovascular events, including myocardial infarction, unstable angina, sudden cardiac death, ventricular arrhythmia, cerebrovascular haemorrhage, transient ischaemic attack, hypertension and hypotension have been reported post-marketing in temporal association with the use of sildenafil.
Teški kardiovaskularni događaji, uključujući infarkt miokarda, nestabilnu anginu, iznenadnu srčanu smrt, ventrikularnu aritmiju, cerebrovaskularno krvarenje, tranzitornu ishemijsku ataku, hipertenziju i hipotenziju bili su prijavljeni u razdoblju nakon stavljanja lijeka u promet, kao vremenski povezani s primjenom sildenafila.
Do not take Sildenafil Teva film-coated tablets in combination with sildenafil-containing orodispersible tablets.
Nemojte uzeti Sildenafil Teva filmom obložene tablete u kombinaciji s raspadljivim tabletama za usta koje sadrže sildenafil.
− If you experience sudden decrease or loss of vision, stop taking Sildenafil Teva and contact your doctor immediately.
• Ako osjetite iznenadno slabljenje ili gubitak vida, prestanite uzimati Sildenafil Teva i odmah zatražite savjet liječnika.
If you experience any of the following serious side effects stop taking Sildenafil Teva and seek medical help immediately:
Ako primijetite bilo koju od sljedećih nuspojava, prestanite uzimati lijek Sildenafil Teva i odmah zatražite medicinsku pomoć:
You should not use Sildenafil Teva with treatments for pulmonary arterial hypertension (PAH) containing sildenafil or any other PDE5 inhibitors.
Ne smijete uzimati Sildenafil Teva zajedno s terapijom za plućnu arterijsku hiperteniziju (PAH) koja sadrži sildenafil ili neke druge inhibitore PDE5.
Although specific interaction studies were not conducted for all medicinal products, population pharmacokinetic analysis showed no effect of concomitant treatment on sildenafil pharmacokinetics when grouped as CYP2C9 inhibitors (such as tolbutamide, warfarin, phenytoin), CYP2D6 inhibitors (such as selective serotonin reuptake inhibitors, tricyclic antidepressants), thiazide and related diuretics, loop and potassium sparing diuretics, angiotensin converting enzyme inhibitors, calcium channel blockers, beta-adrenoreceptor antagonists or inducers of CYP450 metabolism (such as rifampicin, barbiturates).
Iako specifična ispitivanja interakcija nisu provedena za sve lijekove, populacijska farmakokinetička analiza nije ukazala na djelovanje istodobno primijenjenih terapija na farmakokinetiku sildenafila, grupiranih kao CYP2C9 inhibitori (kao što su tolbutamid, varfarin, fenitoin), CYP2D6 inhibitori (kao što su selektivni inhibitori ponovne pohrane serotonina, triciklični antidepresivi), tiazid i srodni diuretici, diuretici Henleove petlje i oni koji štede kalij, inhibitori angiotenzin konvertirajućeg enzima,
*Reported during post-marketing surveillance only **Visual colour distortions: Chloropsia, Chromatopsia, Cyanopsia, Erythropsia and Xanthopsia ***Lacrimation disorders: Dry eye, Lacrimal disorder and Lacrimation increased
*Prijavljeno isključivo nakon stavljanja lijeka u promet ** Vizualni poremećaj percepcije boja: kloropsija, kromatopsija,cijanopsija, eritropsija i ksantopsija *** Poremećaji suzenja: suho oko, suzni poremećaji i pojačano suženje
The following groups were not well represented or excluded from clinical trials: patients with pelvic surgery, patients post-radiotherapy, patients with severe renal or hepatic impairment and patients with certain cardiovascular conditions (see section 4.3).
Sljedeće skupine nisu dobro zastupljene ili su isključene iz kliničkih ispitivanja: bolesnici s operacijom u području zdjelice, bolesnici nakon radioterapije, bolesnici s teškim poremećajem funkcije bubrega ili jetre i bolesnici s određenim kardiovaskularnim stanjima
How to take Sildenafil Teva
Kako uzimati Sildenafil Teva
− If you have sickle cell anaemia (an abnormality of red blood cells), leukaemia (cancer of blood cells), multiple myeloma (cancer of bone marrow)
• Ako imate anemiju srpastih stanica (poremećaj crvenih krvnih stanica), leukemiju (zloćudnu bolest krvnih stanica), multipli mijelom (zloćudnu bolest koštane srži)
Paediatric population Sildenafil Teva is not indicated for individuals below 18 years of age.
Pedijatrijska populacija Sildenafil Teva nije indiciran za primjenu u osoba mlađih od 18 godina.
Store in the original package in order to protect from moisture
Čuvati u originalnom pakiranju radi zaštite od vlage
Common (≥ 1/100 and
(≥ 1/100 do
Always tell your doctor, pharmacist or nurse if you are taking any of these medicines that are often used for the relief of angina pectoris (or “chest pain”).
Uvijek obavijestite svog liječnika, ljekarnika ili medicinsku sestru ako uzimate bilo koji od ovih lijekova koji se često primjenjuju za ublažavanje angine pektoris (ili boli u prsima).
In volunteers with mild to moderate hepatic cirrhosis (Child-Pugh A and B) sildenafil clearance was reduced, resulting in increases in AUC (84 %) and Cmax (47 %) compared to age-matched volunteers with no hepatic impairment.
U dobrovoljaca s blagom do umjerenom cirozom jetre (Child-Pugh A i B) klirens sildenafila bio je snižen, što je rezultiralo porastom AUC (84%) i Cmax (47%) u usporedbi s dobrovoljcima odgovarajućim po dobi bez oštećenja jetre.
Myocardial infarction, Ventricular arrhythmia,* Atrial fibrillation, Unstable angina
Iznenadna srčana smrt,* infarkt miokarda, ventrikularna aritmija,* fibrilacija atrija, nestabilna angina
Sildenafil Teva contains the active substance sildenafil which belongs to a group of medicines called phosphodiesterase type 5(PDE5) inhibitors.
Sildenafil Teva sadrži djelatnu tvar sildenafil koja pripada skupini lijekova pod nazivom inhibitori fosfodiesteraze tipa 5 (PDE5).
31-546, Krakow, Poland
Teva Operations Poland Sp.z.o.o. ul Mogilska 80. 31-546, Krakow, Poljska
Uncommon (may affect up to 1 in 100 people): vomiting, skin rash, eye irritation, bloodshot eyes /red eyes, eye pain, seeing flashes of light, visual brightness, light sensitivity, watery eyes, pounding heartbeat, rapid heartbeat, high blood pressure, low blood pressure, muscle pain, feeling sleepy, reduced sense of touch, vertigo, ringing in the ears, dry mouth, blocked or stuffy sinuses, inflammation of the lining of the nose (symptoms include runny nose, sneezing and stuffy nose), upper abdominal pain, gastro-oesophageal reflux disease (symptoms include heartburn), presence of blood in urine, pain in the arms or legs, nosebleed, feeling hot and feeling tired.
Manje često (mogu se javiti kod najviše 1 na 100 osoba): povraćanje, kožni osip, iritacija oka, krvave oči/crvene oči, bol u očima, bljeskovi pred očima, osjećaj svjetline pri gledanju, osjetljivost na svjetlo, suzenje očiju, lupanje srca, ubrzani otkucaji srca, visoki krvni tlak, niski krvni tlak, bol u mišićima, osjećaj pospanosti, smanjeni osjet dodira, vrtoglavica, zvonjenje u ušima, suha usta, puni ili začepljeni sinusi, upala nosne sluznice (simptomi uključuju curenje iz nosa, kihanje i začepljen nos), bol u gornjem dijelu abdomena, gastroezofagealna refluksna bolest (simptomi uključuju žgaravicu), krv u mokraći, bol u rukama ili nogama, krvarenje iz nosa, osjećaj vrućine i osjećaj umora.
Caution is advised when sildenafil is administered to patients taking an alpha-blocker, as the coadministration may lead to symptomatic hypotension in a few susceptible individuals (see section 4.5).
Prilikom primjene sildenafila u bolesnika koji uzimaju alfa-blokator savjetuje se oprez jer istodobna primjena može dovesti do simptomatske hipotenzije u manjeg broja osjetljivih osoba (vidjeti dio 4.5).
The side effects reported in association with the use of Sildenafil Teva are usually mild to moderate and of a short duration.
Nuspojave zabilježene kod primjene lijeka Sildenafil Teva obično su blage do umjerene i kratko traju.
Non-arteritic anterior ischaemic optic neuropathy (NAION), * Retinal vascular occlusion,* Retinal haemorrhage, Arteriosclerotic retinopathy, Retinal disorder, Glaucoma, Visual field defect,
Nearteritična anteriorna ishemijska optička neuropatija (NAION), * retinalna vaskularna okluzija,* retinalno krvarenje, arteriosklerotska retinopatija, porem ećaj mrežnice,
− If you are taking medicines called nitrates, as the combination may lead to a dangerous fall in your blood pressure.
• Ako uzimate lijekove koji se nazivaju nitrati, jer kombinacija može dovesti do opasnog pada krvnog tlaka.
Pooling of the following classes of antihypertensive medication: diuretics, beta-blockers, ACE inhibitors, angiotensin II antagonists, antihypertensive medicinal products (vasodilator and centrallyacting), adrenergic neurone blockers, calcium channel blockers and alpha-adrenoceptor blockers, showed no difference in the side effect profile in patients taking sildenafil compared to placebo treatment.
inhibitora, antagonista angiotenzina II, antihipertenzivnih lijekova (vazodilatatora i onih sa središnjim djelovanjem), blokatora adrenergičkog neurona, blokatora kalcijevih kanala i blokatora alfaadrenoceptora, nije pokazala razlike u profilu nuspojava u bolesnika koji uzimaju sildenafil u usporedbi s liječenjem placebom.
The safety profile of sildenafil is based on 9,570 patients in 74 double-blind placebo-controlled clinical studies.
Profil sigurnosti sildenafila temelji se na podacima dobivenim od 9570 bolesnika koji su sudjelovali u
In volunteers with severe renal impairment (creatinine clearance <30 mL/min), sildenafil clearance was reduced, resulting in mean increases in AUC and Cmax of 100 % and 88 % respectively compared to age-matched volunteers with no renal impairment.
U dobrovoljaca s teškim poremećajem bubrega (klirens kreatinina <30 ml/min), klirens sildenafila bio je snižen, što je rezultiralo srednjim porastom AUC i Cmax od 100%, odnosno 88% u usporedbi s dobrovoljcima odgovarajućim po dobi bez oštećenja bubrega.
2 film-coated tablets 4 film-coated tablets 8 film-coated tablets 10 x 1 film-coated tablet 12 film-coated-tablets 24 film-coated tablets
2 filmom obložene tablete 4 filmom obložene tablete 8 filmom obloženih tableta 10 x 1 filmom obloženih tableta 12 filmom obloženih tableta 24 filmom obloženih tableta
You may experience an increase in side effects and their severity.
Mogli biste imati brojnije i jače nuspojave.
In order to minimise the potential for developing postural hypotension, patients should be hemodynamically stable on alpha-blocker therapy prior to initiating sildenafil treatment.
Kako bi se smanjila mogućnost razvoja posturalne hipotenzije, bolesnici moraju biti hemodinamički stabilni uz liječenje alfa blokatorom prije početka liječenja sildenafilom.
2 film-coated tablets 4 film-coated tablets 8 film-coated tablets 10 x 1 film-coated tablet 12 film-coated-tablets
2 filmom obložene tablete 4 filmom obložene tablete 8 filmom obloženih tableta 10 x 1 filmom obloženih tableta 12 filmom obloženih tableta
This is most likely to occur within 4 hours post sildenafil dosing (see sections 4.2 and 4.4).
sata nakon primjene doze sildenafila (vidjeti dijelove 4.2 i 4.4).
What you need to know before you take sildenafil Teva Do not take Sildenafil Teva
Što morate znati prije nego počnete uzimati Sildenafil Teva
You should not take Sildenafil Teva if you are taking medicines called nitrates, as the combination of these medicines may lead to a dangerous fall in your blood pressure.
Ne smijete uzimati Sildenafil Teva ako uzimate lijekove koji se nazivaju nitrati, jer kombinacija ovih lijekova može dovesti do opasnog pada krvnog tlaka.
How to store Sildenafil Teva
Kako čuvati Sildenafil Teva
Rare (may affect up to 1 in 1,000 people): fainting, stroke, heart attack, irregular heartbeat, temporary decreased blood flow to parts of the brain, feeling of tightening of the throat, numb mouth, bleeding at the back of the eye, double vision, reduced sharpness of vision, abnormal sensation in the eye, swelling of the eye or eyelid, small particles or spots in your vision, seeing halos around lights, dilation of the pupil of the eye, discolouration of the white of the eye, penile bleeding, presence of blood in semen, dry nose, swelling of the inside of the nose, feeling irritable and sudden decrease or loss of hearing.
nepravilni otkucaji srca, privremeno smanjenje protoka krvi u određene dijelove mozga, osjećaj stezanja u grlu, gubitak osjeta u ustima, krvarenje u očnoj pozadini, dvostruki vid, smanjena oštrina vida, neuobičajen osjet u oku, oticanje oka ili očnog kapka, sitne čestice ili mrlje u vidnom polju, aureole oko izvora svjetlosti, širenje zjenice oka, promjena boje bjeloočnice, krvarenje iz penisa, krv u sjemenoj tekućini, suhoća nosne sluznice, oticanje unutrašnjosti nosa, osjećaj razdražljivosti i iznenadno smanjenje ili gubitak sluha.
Sildenafil Teva 100 mg film-coated tablets EU/1/09/584/014
Sildenafil Teva 100 mg filmom obložene tablete EU/1/09/584/014
In single dose volunteer studies of doses up to 800 mg, adverse reactions were similar to those seen at lower doses, but the incidence rates and severities were increased.
nuspojave su bile slične onima uočenim pri nižim dozama, međutim stope incidencije i težina bile su povećane.
This metabolite has a phosphodiesterase selectivity profile similar to sildenafil and an in vitro potency for PDE5 approximately 50 % that of the parent drug.
Ovaj metabolit ima profil selektivnosti za fosfodiesterazu koji je sličan sildenafilu te in vitro djelovanje na
Tablet core: microcrystalline cellulose, calcium hydrogen phosphate anhydrous, croscarmellose sodium, magnesium stearate.
Jezgra tablete celuloza, mikrokristalična kalcijev hidrogenfosfat, bezvodni karmelozanatrij, umrežena magnezijev stearat
You should not use Sildenafil Teva with any other oral or local treatments for erectile dysfunction.
Ne smijete uzimati Sildenafil Teva s drugim oralnim (primijenjenim kroz usta) ili lokalnim lijekovima za erektilnu disfunkciju (poremećaj erekcije).
• Serious skin reactions - this occurs rarely.
• Jake kožne reakcije - javljaju se rijetko
Penile haemorrhage, Priapism,* Haematospermia , Erection increased
Penilna hemoragija, Prijapizam, * hematospermija, produžena erekcija
Sildenafil Teva 50 mg film-coated tablets EU/1/09/584/008
Sildenafil Teva 50 mg filmom obložene tablete EU/1/09/584/008
Co-administration of the HIV protease inhibitor ritonavir, which is a highly potent P450 inhibitor, at steady state (500 mg twice daily) with sildenafil (100 mg single dose) resulted in a 300 % (4-fold) increase in sildenafil Cmax and a 1,000 % (11-fold) increase in sildenafil plasma AUC.
Istodobna primjena inhibitora HIV proteaze, ritonavira, koji je jaki P450 inhibitor, u stanju dinamičke ravnoteže (500 mg dva puta dnevno) sa sildenafilom (100 mg u jednoj dozi) rezultirala je 300%-tnim (4 puta) porastom Cmax sildenafila i 1000%-tnim (11 puta) porastom AUC sildenafila u plazmi.
Sildenafil Teva 25 mg film-coated tablets EU/1/09/584/002
Sildenafil Teva 25 mg filmom obložene tablete EU/1/09/584/002
However, you may find that Sildenafil Teva takes longer to start working if you take it with a heavy meal.
Međutim, ako uzmete Sildenafil Teva uz obilniji obrok, možda će proći više vremena do početka njegovog djelovanja.
Your doctor should carefully check whether your heart can take the additional strain of having sex.
Vaše srce podnijeti dodatni napor spolnog odnosa.
Myopia,
Mučnina,
Co-administration of the HIV protease inhibitor saquinavir, a CYP3A4 inhibitor, at steady state (1200 mg three times a day) with sildenafil (100 mg single dose) resulted in a 140 % increase in sildenafil Cmax and a 210 % increase in sildenafil AUC.
Istodobna primjena inhibitora HIV proteaze, sakvinavira, inhibitora CYP3A4, u stanju dinamičke ravnoteže (1200 mg tri puta dnevno) sa sildenafilom (100 mg u jednoj dozi) rezultirala je 140%-tnim porastom Cmax sildenafila i 210%-tnim porastom AUC sildenafila.
If Sildenafil Teva does not help you to get an erection, or if your erection does not last long enough for you to complete sexual intercourse you should tell your doctor.
Trebate obavijestiti svog liječnika ako Vam Sildenafil Teva ne pomaže u postizanju erekcije ili ukoliko erekcija ne traje dovoljno dugo za dovršetak spolnog odnosa.
A. MANUFACTURERS RESPONSIBLE FOR BATCH RELEASE
DODATAK II A. PROIZVOĐAČI ODGOVORNI ZA PUŠTANJE SERIJE LIJEKA U PROMET
Uncommon (≥ 1/1,000 and
(≥ 1/1000 do
No significant interactions were shown when sildenafil (50 mg) was co-administered with tolbutamide (250 mg) or warfarin (40 mg), both of which are metabolised by CYP2C9.
(250 mg) ili varfarinom (40 mg), lijekovima koji se metaboliziraju putem CYP2C9.
The total body clearance of sildenafil is 41 L/h with a resultant terminal phase half-life of 3-5 h. After either oral or intravenous administration, sildenafil is excreted as metabolites predominantly in the faeces (approximately 80 % of administered oral dose) and to a lesser extent in the urine (approximately 13 % of administered oral dose).
Nakon peroralne ili intravenske primjene, sildenafil se izlučuje u obliku metabolita, uglavnom stolicom (približno 80% primijenjene oralne doze) i u manjoj mjeri mokraćom (približno 13%
Marketing Authorisation Holder and Manufacturer Marketing Authorisation Holder
Nositelj odobrenja za stavljanje lijeka u promet i proizvođač
In particular, sildenafil has greater than 4,000-fold selectivity for PDE5 over PDE3, the cAMP-specific phosphodiesterase isoform involved in the control of cardiac contractility.
700 puta u usporedbi s PDE2, 3, 4, 7, 8, 9, 10 i 11. Posebno, sildenafil ima preko 4000 puta veću selektivnost za PDE5 u usporedbi s PDE3, cAMP-specifičnoj izoformi fosfodiesteraze uključenoj u kontrolu kontraktilnosti srca.
In healthy volunteers receiving sildenafil (100 mg single dose), less than 0.0002 % (average 188 ng) of the administered dose was present in ejaculate 90 minutes after dosing.
U zdravih dobrovoljaca koji su primali sildenafil (100 mg u jednokratnoj dozi), manje od 0,0002%
6.6 Special precautions for disposal and other handling
6.6 Posebne mjere za zbrinjavanje
You should not take Sildenafil Teva if you are using any of the medicines known as nitric oxide donors such as amyl nitrite (“poppers”) as the combination may also lead to a dangerous fall in your blood pressure.
Ne smijete uzimati Sildenafil Teva ako uzimate bilo koje od lijekova poznatih kao donori dušikovog oksida poput amil nitrita, jer kombinacija, također, može dovesti do opasnog pada krvnog tlaka.
In a study of healthy male volunteers, co-administration of the endothelin antagonist, bosentan, (an inducer of CYP3A4 [moderate], CYP2C9 and possibly of CYP2C19) at steady state (125 mg twice a day) with sildenafil at steady state (80 mg three times a day) resulted in 62.6% and 55.4% decrease in sildenafil AUC and Cmax, respectively.
U ispitivanju sa zdravim muškim dobrovoljcima, istodobna primjena antagonista endotelina, bosentana (induktor CYP3A4 [umjereni], CYP2C9 i vjerojatno CYP2C19), u stanju dinamičke ravnoteže (125 mg dva puta dnevno) sa sildenafilom u stanju dinamičke ravnoteže
Sildenafil Teva is available in blister packs of 2, 4, 8 and 12 tablets, and perforated unit dose blisters containing 10 x 1 tablet.
Sildenafil Teva dostupan je u blisterima od 2, 4, 8 i 12 tableta, te u perforiranim blisterima djeljivim na jedinične doze koji sadrže 10 x 1 tabletu.
Sildenafil Teva is available in blister packs of 2, 4, 8, 12 and 24 tablets, and perforated unit dose blisters containing 10 x 1 tablet.
Sildenafil Teva dostupan je u blisterima od 2,4, 8, 12 i 24 tableta, te u perforiranim blisterima djeljivim na jedinične doze koji sadrže 10 x 1 tabletu.